桥接还是负担?当代分配时代左心室辅助装置撤除后的心脏移植结局
该单中心回顾性研究纳入2020年1月至2024年12月432例心脏移植受者,比较原发胸骨切开、非LVAD再次胸骨切开与LVAD撤除三组的输血、血管麻痹及死亡结局。LVAD撤除组输血量、血管麻痹及1年、2年死亡风险均高于原发胸骨切开组,提示LVAD撤除标识更高危移植表型。
要点
- LVAD撤除组血管麻痹发生率22.9%,原发胸骨切开组12.1%,校正后LVAD撤除仍与更高血管麻痹风险相关。
- LVAD撤除组1年生存率87.6%、2年85.2%,低于原发胸骨切开组的98.3%和95.0%。
- LVAD撤除组校正后1年死亡风险为原发胸骨切开组的5.8倍,2年为2.9倍。
核心结论
- 心脏移植时LVAD撤除与原发胸骨切开相比,与更多输血、血管麻痹及早期至中期死亡相关。
- LVAD撤除标识由手术负担、装置相关生理效应及分配时代移植时机塑造的高危移植表型,而非单纯装置内在风险。
研究设计与样本
- 单中心回顾性研究,纳入2020年1月至2024年12月心脏移植受者432例。
- 排除多器官移植、先天性心脏病、≥2次既往胸骨切开、非HeartMate 3 LVAD或移植前ECMO患者。
- 受者分为原发胸骨切开组237例、非LVAD再次胸骨切开组90例、LVAD撤除组105例。
- 采用逆概率治疗加权逻辑回归和Cox模型评估血管麻痹与死亡。
主要发现
- 术中及术后48小时输血量在三组间逐步增加(均P < .001)。
- 血管麻痹发生率分别为原发胸骨切开12.1%、非LVAD再次胸骨切开24.3%、LVAD撤除22.9%(P = .014)。
- 逆概率治疗加权校正后,LVAD撤除组血管麻痹风险仍高于原发胸骨切开组(OR 2.2 [1.1-4.4],P = .03)。
- 未校正1年生存率分别为98.3%、93.3%、87.6%(P < .001),2年生存率分别为95.0%、89.1%、85.2%(P = .003)。
- 与B原发胸骨切开组相比,LVAD撤除组校正后1年死亡风险HR 5.8(95% CI 1.8-19,P = .003),2年HR 2.9(95% CI 1.3-6.7,P = .01)。
临床怎么用
- 心脏移植前应评估LVAD撤除患者输血、血管麻痹及死亡风险增高,优化围术期管理。
- LVAD撤除患者可考虑作为高危移植表型进行更密切的术后监测与资源准备。
局限性
- 单中心回顾性设计,结果外推需谨慎。
- 排除标准较多(如非HeartMate 3 LVAD、移植前ECMO等),限制普遍适用性。
- 低风险LVAD撤除亚组样本量小(n = 37),探索性结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether left ventricular assist device (LVAD) explantation during heart transplantation confers additional risk remains unsettled in the contemporary allocation era. METHODS: Heart transplant recipients at a single center (January 2020 to December 2024) were retrospectively reviewed. Patients undergoing multiorgan transplantation, patients with congenital heart disease, with ≥2 prior sternotomies, with non-HeartMate 3 (Abbott) LVADs, or undergoing pretransplantation ECMO were excluded. Recipients were grouped as primary sternotomy, non-LVAD redo sternotomy, or LVAD explant. Outcomes included transfusions, vasoplegia, and 30-day, 1-year, and 2-year mortality. Inverse probability of treatment weights-weighted logistic regression and Cox models assessed vasoplegia and mortality. RESULTS: Among 432 recipients (primary sternotomy, 237; non-LVAD redo sternotomy, 90; LVAD explant, 105), transfusion volumes increased stepwise intraoperatively and 48 hours postoperatively (both P < .001). Vasoplegia differed across cohorts (12.1% vs 24.3% vs 22.9%, respectively; P = .014); after inverse probability of treatment weights adjustment, LVAD explant remained associated with higher odds vs primary sternotomy (odds ratio, 2.2 [1.1-4.4]; P = .03). Unadjusted survival declined across groups at 1 year (98.3% vs 93.3% vs 87.6%, respectively; P < .001) and 2 years (95.0% vs 89.1% vs 85.2%, respectively; P = .003). Compared with the primary sternotomy group, the LVAD explant group had higher adjusted hazards of death at 1 year (hazard ratio, 5.8 [95% CI, 1.8-19]; P = .003) and 2 years (hazard ratio, 2.9 [95% CI, 1.3-6.7]; P = .01). In an exploratory lower-risk LVAD explant subgroup (n = 37), observed mortality differences were attenuated. CONCLUSIONS: LVAD explantation during heart transplant was associated with greater transfusions, vasoplegia, and early-to-intermediate mortality compared with primary sternotomy. These findings suggest that LVAD explantation identifies a higher-risk transplant phenotype shaped by surgical burden, device-associated physiologic effects, and allocation-era transplantation timing, rather than by intrinsic device-related risk alone.
引用
- Navid W, Wang CC, Ahmad A, et al. Bridge or Burden? Heart Transplant Outcomes After Left Ventricular Assist Device Explant in the Contemporary Allocation Era. Ann Thorac Surg. 2026. PMID: 42556451. doi:10.1016/j.athoracsur.2026.07.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。